Clinical trial
Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention…
NCT00142961 · New York State Psychiatric Institute, Other · Completed
Key facts
| NCT number | NCT00142961 |
|---|---|
| Title | Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder |
| Official title | Marijuana-Abusing Attention Deficit Hyperactivity Disorder (ADHD) Teens: Atomoxetine Treatment |
| Lead sponsor | New York State Psychiatric Institute, Other |
| Collaborators | National Institute on Drug Abuse (NIDA) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Attention Deficit Disorder With Hyperactivity, Marijuana Abuse |
| Intervention type | Drug, Other |
| Interventions | Atomoxetine, placebo |
| Enrollment | 2 |
| Start date | Oct 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Sep 2, 2005 |
| Last update posted | Apr 23, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: